-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4739 Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Diseases, Adverse Events, Myeloid Malignancies, Maternal Health
Monday, December 12, 2022, 6:00 PM-8:00 PM

Katja Sockel, MD1*, Sandra Frank2*, Annika Neu3*, Markus Ditschkowski, PhD4*, Inken Hilgendorf5*, Mareen Goeckenjan6*, Friedrich Stoelzel, MD3, Jan Moritz Middeke, MD3*, Nicolaus Kröger, MD7*, Francis A. Ayuk, MD8*, Matthias Eder, MD9*, Wolfgang Bethge, MD10*, Jürgen Finke, MD, PhD11, Hartmut Bertz, MD12*, Guido Kobbe, MD13*, Martin Kaufmann, MD14, Uwe Platzbecker, MD15, David Beverungen, MD15*, Christoph Schmid, MD16*, Malte von Bonin, MD17*, Katharina Egger-Heidrich, MD3*, Lisa Heberling3*, Karolin Trautmann-Grill, MD3*, Raphael Teipel, MD3*, Gesine Bug, MD18*, Johanna Tischer, MD19*, Alessia Fraccaroli, MD20*, Barbara Holler21*, Daniel Wolff, MD22*, Thomas Luft, MD, PhD23, Wolf Roesler, M.D.24*, Kerstin Schäfer-Eckart25*, Sabine Dressler26*, Christof Scheid27, Udo Holtick, MD, PhD28*, Stefan Klein, MD29*, Igor Wolfgang Blau, MD30*, Andreas Burchert, MD31, Gerald Wulf, MD32*, Justin Hasenkamp32*, Rainer Schwerdtfeger, MD33*, Stephan Kaun, MD34*, Christoph Wittke35*, Friederike Wortmann36*, Helga Neidlinger37*, Martin Bornhaeuser, MD3, Johannes Schetelig, MD3 and on Behalf of the German Cooperative Transplant Study Group38*

1Medical Clinic and Policlinic I, University Hospital Dresden, TU Dresden, Dresden, Germany
2Institute of Statistics, University Ulm, Ulm, Germany
3Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany
4University Duisburg-Essen, Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
5Department of Internal Medicine II, University Clinic Jena, Jena University, Jena, Germany
6Department for Gynaecology and Obstetrics, University Hospital Dresden, Technical University Dresden,, Dresden, Germany
7University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation, Hamburg, Germany
8Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
9Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
10Department of Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany
11Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg, Germany
12Department of Hematology/Oncology/Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany
13Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany
142nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital, Stuttgart, Germany
15Department of Hematology, Cellular Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany
16Department of Haematology and Oncology, University Hospital and Medical Faculty Augsburg, Augsburg, Germany
17Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Saxony, Germany
18Goethe University Frankfurt, University Hospital, Dept. of Medicine, Hematology and Oncology, Frankfurt, Germany
19Dept of Internal Medicine III, LMU, University Hospital of Munich, Campus Großhadern,, Munich, Germany
20Dept of Internal Medicine III, LMU, University Hospital of Munich, Campus Großhadern, Munich, Germany
21Medical Clinic III, University Medicine Regensburg, Regensburg, Germany
22Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
23Department of Internal Medicine V (Hematology/Oncology/Rheumatology), Heidelberg University Hospital, Heidelberg, Germany
24Department of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany
25Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Germany
26Department of Internal Medicine V, Nuremberg Hospital North, Paracelsus Medical University, Nuremberg, Bavaria, Germany
27Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
28University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
29Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Germany
30Department of BMT, Clinic of Hematology, Oncology and Tumorimmunology, University Medicine Berlin, Berlin, Germany
31Department of Hematology, Oncology and Immunology, Carreras Leukemia Center, Philips Univ. Marburg, Marburg, Hessen, Germany
32University Medicine Göttingen, Hematology and Medical Oncology, Goettingen, Germany
33Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany
34Hematology, Oncology und Infectiology, Clinic Bremen-Mitte, Bremen, Germany
35Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, DEU
36DDepartment of Hematology and Oncology, Medical Center, University of Schleswig-Holstein, Luebeck, Germany
37German registry of stem cell transplantation (DRST), Ulm, Germany
38German Cooperative Transplant Study Group, Dresden, Germany

Background

Long-term survival following allogeneic hematopoietic cell transplantation (alloHCT) has improved significantly over the last decades. Beyond curation, return to a normal social life, including family planning, represents an important goal especially for young adult cancer survivors.

However, alloHCT recipients are at high risk for infertility due to precedent chemotherapy, total body irradiation, transplant-related morbidity and long-term immunosuppressive medication. Nevertheless, spontaneous pregnancies following alloHCT were reported occasionally. Systematic studies on fertility preservation and pregnancies after alloHCT are very rare and do not cover the most recent era of transplantation. To fill this gap, we conducted a national multicenter study to investigate the pregnancy rate after alloHCT and their outcomes and to analyze potential risk factors in female transplant recipients.

Methods

Retrospectively, we evaluated data on disease and transplant characteristics from all women of childbearing age (18-40 years), who received an alloHCT in Germany between 2003 and 2018. Data were retrieved from the German Registry for Stem Cell Transplantation (DRST). Follow-up data were introduced into a competing risk model in order to calculate rates of pregnancies and first live birth per person-year after alloHCT. “First live birth” and “death w/o prior live birth” were considered as competing risks. Cumulative hazards were estimated with the Nelson-Aalen estimator. To perform a risk factor analysis for the expected incidence rate we used multivariable Poisson regression. In addition, we performed structured guideline interviews with those women who consented in providing detailed information about conception, course of pregnancy, and children’s health.

Results

In total, 2,654 women met the eligibility criteria and 74 pregnancies were reported in 50 women. Pregnancies were reported at a median of 4.7 years (0.7-14.7 years) following alloHCT. Women who conceived pregnancy had a median age of 24 years (range 18 to 34) at alloHCT. Underlying diseases were AML/MDS in 19 patients, bone marrow failure syndromes in 17 patients, Lymphoma/ALL in 8 patients, and CML in 6 patients. Most patients underwent non-myeloablative or RIC (NMA/RIC) conditioning (76%). Total body irradiation (TBI) was part of the conditioning regimen in 12 patients (24%) of whom 4 patients received a cumulative TBI dose ≥8 Gray. Notably, acute GVHD grade II-IV had been reported in 11 women and chronic GvHD in 14 women.

Factors associated with a better chance of pregnancy were younger age at alloHCT (p<0.001), TBI with <8 Gray (p<0.020), NMA/RIC conditioning (p= 0.032) and non-malignant transplant indications such as hemoglobinopathy/bone marrow failure syndrome (p=0.006). Fifty-three of 74 pregnancies resulted in live births. Based on competing risk analyses this translated into an annual rate of 0.45% (95% CI: 0.31 to 0.59 %) first-livebirths after alloHCT. This rate is 6 times lower than the corresponding first-birth rate of 3% for german women between 18 and 40 years of age.

Detailed informations on conception and outcomes were obtained for 52 pregnancies. Forty out of 52 (77%) pregnancies occurred spontaneously, while assisted reproductive technologies (ART) were used in the remaining women. Techniques that resulted in successful pregnancies were: IVF (n=2), ICSI (n=2), ovarian tissue cryopreservation (n=2), oocyte donation (n=6). Preterm deliveries (29%) and low birth weight (21%) were higher as compared to reference data for the general population.

Conclusions

Our data strongly indicate that female alloHCT survivors should be educated about the realistic possibility to become pregnant after HCT. Lower age at alloHCT (<35 years), non-myeloablative or reduced-intensity conditioning, cumulative doses of TBI <8 Gray and non-malignant transplant indications increase the chances to preserve fertility.

Interdisciplinary fertility counseling before alloHCT is essential to inform about the possibilities of assisted reproductive technologies. Nevertheless, the chances for spontaneous pregnancies should not be underestimated, and patients should be aware of this to avoid unexpected or unwanted pregnancies. Further research is needed to better understand and tailor procedural choices for conditioning regimens with respect to fertility preservation.

Disclosures: Sockel: Active Biotech: Research Funding; Gilead: Honoraria; SOBI: Honoraria; BMS: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Middeke: Abbvie: Membership on an entity's Board of Directors or advisory committees. Kröger: Takeda: Consultancy, Honoraria; Sanofi: Honoraria; Kite: Honoraria; Neovii: Honoraria, Research Funding; Riemser: Research Funding; DKMS: Research Funding; Amgen: Honoraria; BMS: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Jazz: Honoraria. Ayuk: Medac: Honoraria; Takeda: Honoraria; Mallinckrodt/Therakos: Honoraria, Research Funding; Janssen: Honoraria; Gilead: Honoraria; Celgene/BMS: Honoraria; Miltenyi Biomedicine: Honoraria; Novartis: Honoraria. Finke: Riemser Pharma: Research Funding. Platzbecker: Janssen: Honoraria; BMS/Celgene: Honoraria; Abbvie: Honoraria; Jazz: Honoraria; Silence Therapeutics: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Geron: Honoraria. Schmid: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Research Funding; Abbvie: Research Funding. Teipel: Amgen, BMS/Celgene, Janssen, GSK, Karyopharm, Oncopeptides, Pfizer, Sanofi, Takeda: Honoraria; Janssen; Travel Expenses: Janssen, Amgen: Research Funding. Bug: Gilead: Consultancy, Honoraria; Celgene /BMS: Consultancy, Honoraria; Jazz: Honoraria; Pfizer: Consultancy; Novartis: Consultancy. Wolff: Incyte Corporation: Honoraria; Sanofi: Honoraria; Behring: Honoraria; Novartis: Honoraria, Research Funding. Luft: JAZZ Pharmaceuticals: Honoraria. Scheid: Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Holtick: CLS Behring: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Novartis: Honoraria, Research Funding; Miltenyi Biotech: Honoraria; BMS/Celgene: Honoraria; Kite/Gilead: Honoraria. Burchert: Incyte: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; AOP Health: Honoraria, Research Funding. Wortmann: Blueprint Medicines Corporation, Novartis: Honoraria; Alexion, Medac, and Novartis: Other: Travel Fees.

*signifies non-member of ASH